Q2 Earnings Estimate for ARWR Issued By B. Riley

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Investment analysts at B. Riley issued their Q2 2025 earnings per share estimates for shares of Arrowhead Pharmaceuticals in a note issued to investors on Thursday, December 12th. B. Riley analyst M. Mamtani anticipates that the biotechnology company will post earnings of ($0.62) per share for the quarter. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($3.72) per share. B. Riley also issued estimates for Arrowhead Pharmaceuticals’ Q4 2025 earnings at ($1.02) EPS.

ARWR has been the topic of several other research reports. Piper Sandler cut their price target on shares of Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating on the stock in a report on Wednesday, November 27th. Royal Bank of Canada reiterated an “outperform” rating and issued a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Thursday, September 26th. Sanford C. Bernstein decreased their target price on shares of Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating for the company in a research report on Friday, November 29th. HC Wainwright upped their price target on shares of Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a “buy” rating in a report on Tuesday, December 3rd. Finally, Citigroup reduced their price objective on Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Wednesday, November 27th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Arrowhead Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $42.70.

Arrowhead Pharmaceuticals Trading Down 1.3 %

Shares of NASDAQ:ARWR opened at $21.85 on Monday. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 2.06. Arrowhead Pharmaceuticals has a 52-week low of $17.05 and a 52-week high of $39.83. The stock has a market cap of $2.72 billion, a price-to-earnings ratio of -4.35 and a beta of 0.91. The business has a 50-day moving average price of $20.98 and a 200-day moving average price of $23.14.

Institutional Trading of Arrowhead Pharmaceuticals

Several institutional investors have recently modified their holdings of the stock. Fifth Third Bancorp boosted its holdings in Arrowhead Pharmaceuticals by 42.5% in the 2nd quarter. Fifth Third Bancorp now owns 1,186 shares of the biotechnology company’s stock worth $31,000 after buying an additional 354 shares during the last quarter. World Investment Advisors LLC boosted its stake in shares of Arrowhead Pharmaceuticals by 3.8% in the third quarter. World Investment Advisors LLC now owns 19,132 shares of the biotechnology company’s stock worth $371,000 after acquiring an additional 700 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Arrowhead Pharmaceuticals by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock worth $88,000 after acquiring an additional 788 shares during the last quarter. Arizona State Retirement System increased its position in shares of Arrowhead Pharmaceuticals by 2.4% during the second quarter. Arizona State Retirement System now owns 34,685 shares of the biotechnology company’s stock worth $901,000 after purchasing an additional 821 shares in the last quarter. Finally, Wellington Management Group LLP raised its stake in Arrowhead Pharmaceuticals by 1.5% in the 3rd quarter. Wellington Management Group LLP now owns 61,904 shares of the biotechnology company’s stock valued at $1,199,000 after purchasing an additional 886 shares during the last quarter. Institutional investors and hedge funds own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.